- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05082350
Nutritional Intervention With Black Garlic
Clinical Trial to Evaluate the Efficacy of Black Garlic in Reducing Cardiovascular Risk in Subjects With Hypercholesterolemia
Study Overview
Status
Intervention / Treatment
Detailed Description
A parallel, controlled clinical trial will be performed to assess the effect of garlic on mild hypercholesterolemia.
The study will conducted in two groups of volunteer: healthy and at cardiovascular risk (hypercholesterolemic subjects), consuming black garlic, with each individual acting as its own control. The study will have a total duration of 18 weeks, divided in two stages:
- Stage 1: basal or washout stage of 2 weeks, in which volunteer follow their usual diet with restrictions
- Stage 2: intervention stage of 16 weeks, in which volunteer consume black garlic Sixty healthy volunteers (men and women) between 40-65 years old and BMI between 24.9-29.9 kg/m2 will be recruited. From the total of volunteer, 30 will correspond to the Healthy Group, which should have total blood cholesterol levels less than 200 mg/dL and LDL-cholesterol less than 135 mg/dL.
The other 30 volunteers correspond to the Cardiovascular Risk Group, which should have total cholesterol levels between 200-300 mg/dL and LDL-cholesterol levels between 135-175 mg/dL.
Other inclusion criteria established for all volunteers are: no acute or chronic pathology, (except hypercholesterolemia for the risk group), no taking drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism.
The study has been approved by the Ethical Committee of Catholic University of Murcia (UCAM) and will be carried out in accordance with the Helsinki Declaration of Human Studies. Recruitment will take place at various Health Centers and at UCAM. All participants will be informed on the characteristics of the study and, after signing the informed consent, a routine analysis will be requested to classify the volunteer in the healthy or cardiovascular risk group.
To avoid bias due to gender, the number of women and men recruited in both groups will be balanced. The size of the study population has been estimated taking total blood cholesterol level as the main variable and taking into account that the study design is randomized and parallel. Considering a statistical power of 80%, a statistical significance level of 5% (one tail), a standard deviation of 6.5, aiming to estimate a difference of 2.5, the number of volunteers required is 25 for each group, rising to 30 in anticipation of dropouts. This number, being two study groups, will allow obtaining results with statistical significance in other biochemical parameters that would be determined as secondary variables of the study and that would inform on the effect of black garlic consumption on cardiovascular function and associated dysfunctions (inflammation, hypertension, endothelial function, diabetes, etc.).
After an initial washout (basal) stage common to all groups, in which the volunteers will consume their usual diet with restriction in the consumption of fresh garlic and garlic products, the intervention will start, with the consumption of black garlic for 12 weeks. Volunteers will be provided with black garlic and they will ensure that no other type of garlic or culinary seasoning is used.
Dietary and physical activity questionnaire according to the "Global Physical Activity Questionnarie (GPAQ)" will be compiled in order to collect information on habits and lifestyle, as well as to ensure the compliance of food restrictions.
During the study, visits will be scheduled on the first day and last day of each stage. The subjects will come to the Unit on fasting conditions and will provide the first morning urine. Blood sample will be taken, plasma aliquoted and stored at -80°C until analysis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Murcia, Spain, 30107
- Universidad Católica de Murcia (UCAM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy Group:
- Total blood cholesterol levels of less than 200 mg/dL
- LDL-cholesterol levels of less than 135 mg/dL
- Not suffer from any other pathology.
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.
Cardiovascular Risk Group:
- Total cholesterol levels between 200-300 mg/dL
- LDL-cholesterol levels between 135-175 mg/dL.
- No acute or chronic pathology, except hypercholesterolemia
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.).
Exclusion Criteria:
- Failure to meet any of the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Group,
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
|
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
|
Experimental: Hypercholesterolemia
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
|
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact on blood pressure
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Blood pressure (diastolic, systolic)
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Impact on lipid profile
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B.
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact on blood cells (Hematology)
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Blood counts
|
changes observed from baseline at day 0 compared to 12 weeks.
|
evaluation of liver function to determine product safety
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Hepatic enzymes (GOT, GPT)
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Changes in cytokine levels
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of pro-inflammatory: IL-1β, IL6 , TNF-α (tumor necrosis factor) and anti-inflammatory (IL-10, IL-17) cytokines.
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Changes in chemokine MCP-1 (monocyte chemotactic protein)
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of chemokine MCP-1
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Changes in C reactive protein
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of C reactive protein
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Impact on endothelial function
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of nitric oxide, adhesion molecules VCAM-1 (vascular endothelial cell adhesion molecule), ICAM-1 (intercellular adhesion molecule), chemokines as markers of endothelium (E-selectin) and platelet (P-selectin) activation.
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Impact on glucose levels
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of glucose
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Impact on glycosylated hemoglobin (HbA1c)
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of glycosylated hemoglobin
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Impact in hormones related to metabolism
Time Frame: changes observed from baseline at day 0 compared to 12 weeks.
|
Plasma levels of thyroid hormones (TSH, T3, T4).
|
changes observed from baseline at day 0 compared to 12 weeks.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CFE/IF/28-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on black garlic
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació... and other collaboratorsCompleted
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)Completed
-
Weill Medical College of Cornell UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Cornell...RecruitingObesity, Childhood | Type2DiabetesUnited States
-
Ramsar international campusCompleted
-
University of Massachusetts, AmherstCompletedAbsorption | Black Pepper | CarotenoidUnited States
-
Rush University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsRecruitingDiabetes Mellitus | Adolescent ObesityUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)Completed
-
The Center for Applied Health Sciences, LLCBrightseed, IncCompletedInflammation | Triglycerides | Appetite | Lipids | Waist CircumferenceUnited States
-
University of Medicine and Pharmacy "Victor Babes...ASCAR Cardiology Clinic, Timisoara City HospitalActive, not recruitingEvaluation of Black Chokeberry Bio Juice on Blood Pressure Levels and Endothelial Damage (AROBLENDO)Inflammation | Essential Hypertension | Endothelial DysfunctionRomania
-
Natural Immune Systems IncNew Chapter Inc.CompletedHyperglycemia | HyperlipidemiasUnited States